The UK's Office of Fair Trading is suggesting a system of drug pricing based on therapeutic value, which it believes would better focus innovation and investment toward creating more valuable drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Democrats prioritize pricing, generics and drug safety
US aims to tighten rules on direct-to-consumer drug ads
Web links
European Platform for Patients' Organizations, Science and Industry
Rights and permissions
About this article
Cite this article
Moran, N. UK parses merits of value-based drug pricing. Nat Biotechnol 25, 369–370 (2007). https://doi.org/10.1038/nbt0407-369
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0407-369